HOOKIPA and Roche Enter into a License Agreement to Develop HB-700 and Arenaviral Immunotherapies for KRAS-Mutated Cancers
Shots:
- Under the terms of the collaboration, HOOKIPA will receive an upfront payment of $25M, an aggregate of $335M for the R&D of HB-700 & $250M as sales-based milestones. Whereas for the undisclosed novel arenaviral immunotherapy HOOKIPA will receive a $15M payment if the option is exercised & an aggregate of $173M as an event-based milestone for R&D & $160M in sales-based milestones
- HOOKIPA will be responsible for the development of HB-700 whereas, upon completion of the P-Ib study, Roche will be eligible for the development & commercialization responsibility
- HB-700 is a replicating 2-vector therapy developed for the treatment of KRAS-mutated lung, colorectal, pancreatic & other cancer indications
Ref: GlobeNewswire | Image: Hookipa
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
